PPL-Therapeutics - 500 Beiträge pro Seite



Beitrag schreiben

Begriffe und/oder Benutzer

 

Wieso werden seit 3 Tagen mit steigenden Kursen
Aktien geordert?
Ist da etwas im Bush?
Wer weiß mehr dazu?
Neuer Klonerfolg in England!
PPL teilt mit, das identische kleine Ferkel erzeugt worden sind, die in den folgenden klinischen Tests als Ersatzteillieferanten für Menschen dienen sollen.
So nebenbei will man den Cashburn drastisch reduzieren.
Wer sagts denn.
Quelle: Stockhouse.gbr
Hier der Originalwortlaut und die richte Seite:
www.stockhouse.co.uk (natürlich nicht gbr, so ein quatsch)



PPL hopes its piglets will help to prevent organ rejection


THURSDAY APRIL 12 2001

PPL unveils modified piglets

BY MARK COURT, HEALTH INDUSTRIES CORRESPONDENT

PPL THERAPEUTICS, the biotechnology company that was forced to abandon a £45 million fundraising this week, yesterday bounced back when it became the world’s first company to produce genetically modified piglets as part of its attempt to transplant pig organs into people.

The five piglets are both transgenic, in that they have had a non-pig gene inserted into their chromosomes, and cloned, so their genetic make-up is identical.

Alan Colman, PPL research director, said: “This exciting world first again demonstrates PPL’s ability to apply its technical expertise to unmet medical needs such as the worldwide organ shortage.’’

PPL now intends to produce a transgenic piglet with a genetic modification in an attempt to prevent the rejection of pig organs if they were to be transplanted into people.

Clinical trials might begin in four to five years’ time and the market for organs such as lungs is estimated to be worth $5 billion.

Ron James, managing director of PPL, the company which created Dolly the sheep, yesterday bought 10,000 shares to underline his confidence in the company, which is being forced to explore funding alternatives after the failure of its £45 million cash call on Tuesday.

PPL is thought to be considering a smaller cash call of up to £25 million, which could probably be raised from existing shareholders. The company, whose shares closed down 2p yesterday at 111p, has enough cash for one year but needs longer-term funding in the next few months.



Copyright 2001 Times Newspapers Ltd. This service is provided on Times Newspapers` standard terms and conditions. To inquire about a licence to reproduce material from The Times, visit the Syndication website.





Breaking
Business News
from PA

April 12, 2001 09:24
Auch wenn es etwas still um die "Schweinekloner" geworden ist, so ist man in England nicht untätig geblieben.
Man plant den Bau einer Produktionstätte von AAT (weiß nicht was das ist und wozu) in Zusammenarbeit mit Bayer und der RSB (Royal Scotish Bank)im Volumen von $42 mio.
Die Vermarktungsrechte für diesen Wirkstoff erhält Bayer.
Gleichzeitig kann PPL seinen Cashbedarf für dieses Projekt reduzieren.
Die Erprobung soll 2001 in die Phase III gehen.
Meldung vom 12.7.2001 unter www.ppl-therapeutics.com
Wenn Bayer so viel Geld investiert (15 Mio.) scheint etwas dran zu sein.
Ich werde sie wieder mal in meine watchliste aufnehmen, zumal die shares fast den 52 Wochen Tiefststand erreicht haben. Aktuell: 1,25 Euro.
CU
For more information contact:
PPL Therapeutics plc:
April D`Arcy
Tel: +44 (0) 131 440 4777


Financial PR Enquiries:
Alistair Mackinnon-Musson
Philip Dennis
Hudson Sandler
Tel: +44 (0) 20 7796 4133


WORLD’S FIRST ANNOUNCEMENT OF CLONED ‘KNOCK-OUT’ PIGS


Christmas-born pigs are a major step towards successful production of animal organs and cells for human transplantation use

PPL Therapeutics Plc, one of the world’s leading biopharmaceutical companies in the application of transgenic technology to the production of human proteins for therapeutic and nutritional applications, is pleased to announce it has produced ‘knock-out’ piglets which were born as a result of using nuclear transfer (cloning) and PPL’s patented gene targeting technology. The five healthy births took place on Christmas Day, 25 December 2001. It has always been the objective of PPL’s xenotransplantation programme to produce ‘knock-out’ pigs. In future, this vital step should enable organs and/or cells from such animals to be transplanted into humans and not be rejected by the human recipient. A ‘knock-out’ pig has the specific gene that leads to the human immune system rejecting pig organs inactivated.


The announcement today achieves a key milestone that PPL has pursued in the area of xenotransplantation. In view of the fact that PPL’s financial resources are being focused primarily upon bringing its lead product recAAT, for the indication hereditary emphysema, to the market as quickly as possible, PPL proposes to find a ‘spin out’ partner to take the ‘xeno’ and stem cell areas forward. This development demonstrates PPL’s leading position in this area and it will be of significant interest to all companies involved in transplant technology.


Pigs are the preferred species for xenotransplantation on scientific and ethical grounds. It is anticipated the first application of this technology will be the testing of insulin-producing islet cells for the treatment of diabetes from the ‘knock-out’ pigs, first in primates, and soon thereafter in humans. Clinical trials could start in as little as four years and analysts believe the market could be worth over $5 billion for solid organs alone, and $6 billion for cellular therapies for Diabetes, Parkinson’s and Alzheimer’s Diseases.


The gene that has been ‘knocked-out’, the alpha 1,3 galactosyl transferase (GT) gene is responsible for making an enzyme that adds a sugar to the surface of pig cells which is recognised by the human immune system as foreign, and which therefore triggers an immune response leading to hyperacute rejection by the human patient, of the transplanted organ or cell, within minutes. The ability to delete or ‘knock-out’ this gene, therefore, provides a vital step in producing pigs with organs and cells useful in humans.


PPL’s comprehensive xenograft programme relates to both its technology and its Intellectual Property portfolio. In addition to overcoming early hyperacute rejection, the Company has also shown proof-of-concept and has patents for solutions for all aspects of xenograft rejection including delayed xenograft refection, coagulopathy, and chronic T cell mediated rejection. Thus the ‘GT knock-out’ pig will serve as the platform for adding up to three more genes, and include a T cell tolerance regime to address all stages of rejection.


The ‘knock-out’ work was carried out by PPL Therapeutics Inc, PPL’s US subsidiary located in Blacksburg, Virginia, and was partly supported by an ATP Grant from the US Government’s National Institute of Standards and Technology (NIST). The piglets, all females, were confirmed through DNA tests to have one of their two copies of the GT gene inactivated. They have been named: Noel, Angel, Star, Joy and Mary.


Ron James, Director at PPL said:


"Today’s announcement is a natural breakpoint for PPL to spin out the valuable technology it has developed thus far. In light of this news, finding a third party at this particular time to take forward this very exciting area of science, which addresses major markets, will ensure that PPL’s shareholders gain maximum value, whilst protecting the Company’s limited cash resources needed to bring its lead product, recAAT, to market as quickly as possible."


Alan Colman, Research Director at PPL said:


"The successful cloning of these pigs is a major step in achieving PPL’s xenograft objective. Together with the Roslin Institute, we were the first to clone an adult mammal, Dolly. PPL was also the first to demonstrate gene targeting in livestock, the first to clone pigs, and now the first to report alpha 1,3 ‘GT knock-out’ in pigs for xenotransplantation. With one of the major technical hurdles and scientific risks overcome, the promise of xenotransplantation is now a reality, with the potential to revolutionize the transplant industry".


Dr. David Ayares, COO and VP of Research at PPL’s US Division stated:


"The birth of these pigs is a critical milestone in our xenograft programme and should spark renewed vigor from both the scientific and investment communities. This advance provides a near term solution for overcoming the shortage of human organs for transplants as well as insulin-producing cells to cure diabetes.
Stille und leise sind sie (PPL) am klonen und es funktioniert.
Jetzt muß nur noch der Bedarf geweckt werden und dann läuft der Laden.
Man sollte sich wieder ein paar shares ins Depot legen. Günstig sind sie ja noch.;)
Gibt´s Gründe für den dramatischen Kursverfall bei PPL ???
Jetzt schon bei 0,47 € - hat leider meinen Stopp-Loss ausgelöst...
Hallo Jungs!
Wird hier nur Geld verbrannt; oder gibt es auch Neues über
Forschungsergebnisse zu berichten!
Beginnend am 13. Januar:
The Company received notification on 13 January 2002 that, following a sale in
the market of 1,083,970 shares on 8 January 2003, Legal & General Investment
Management Limited now have an interest in 3,980,848 Ordinary shares of 50p each
in the Company, representing 3.35% of the total shares in issue.

The shares are registered as follows:

Registered Owner No. of shares

HSBC Global Custody Nominee 615,843

(UK) Ltd A/c 887711
HSBC Global Custody Nominee 493,158

(UK) Ltd A/c 775245
HSBC Global Custody Nominee 2,871,847

(UK) Ltd A/c 357206
Total 3,980,848

Bis zum 24. schliesslich
RNS Number:5876G
PPL Therapeutics PLC
24 January 2003


PPL Therapeutics plc ("the Company")

DISCLOSURE OF INTEREST

The Company received notification on 23 January 2003 that, following a purchase
of 250,000 shares on 21 January 2003 and 750,000 shares on 22 January 2003,
Credit Suisse First Boston Equities Limited now have an interest in 8,754,110
Ordinary shares of 50p each in the Company, representing 7.09% of the total
shares in issue.

Insgesamt 7 mal gekauft, warum?

Wer hat Informationen?:confused:


Beitrag zu dieser Diskussion schreiben


Es handelt sich hier um eine ältere Diskussion, daher ist das Schreiben in dieser Diskussion nicht mehr möglich. Bitte eröffnen Sie hier eine neue Diskussion.